Apogenix AG

Biotechnology - Therapeutics and Diagnostics

proteona.png

Immunotherapy I Proteins

Apogenix has developed a promising portfolio of innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. These protein therapeutics target different TNFSF-dependent signaling pathways, thereby restoring the anti-tumor immune response, and thus have the potential to transform the treatment of oncological and malignant hematological diseases. The company’s lead immuno-oncology candidate, asunercept, is in late-stage clinical development for the treatment recurrent glioblastoma, the most frequent and aggressive brain tumor.  Apogenix’ scientific team has developed the proprietary HERA-ligand technology platform for the development of novel fusion proteins. In 2017, AbbVie initiated a phase I trial with this HERA-TRAIL receptor agonist (ABBV-621) in patients suffering from solid tumors, non-Hodgkins ́s lymphoma, or acute myeloid leukemia.